Track market-moving stories before they get noisy

- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD)

- Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones

- Incyte will host an analyst and investor call on Monday, June 8, 2026, at 8:00 a.m. ET

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio.

“VGA039 fits directly into our strategy of building a top-tier growth company for the future,” said Bill Meury, Chief Executive Officer of Incyte.

Share Vega Therapeutics’ lead candidate, VGA039, modulates Protein S to improve hemostasis, potentially improving the body’s ability to control bleeding in numerous bleeding disorders. VGA039 is in Phase 3 pivotal development for patients with von Willebrand disease (VWD), the most common inherited bleeding disorder. It has the potential to be the first subcutaneous prophylactic therapy with a convenient dosing regimen for patients with VWD who currently require frequent intravenous infusions.

“VGA039 fits directly into our strategy of building a top-tier growth company for the future,” said Bill Meury, Chief Executive Officer of Incyte. “It is a first-in-class, Phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas – hematology. The transaction has all of the attributes we look for in business development opportunities.”

Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1 The disease is characterized by excessive bleeding that can vary in severity and frequency and may significantly affect quality of life. Current prophylactic treatment options include factor replacement therapies that often require 2 to 3 intravenous infusions each week.2

“This milestone reflects our team’s deep commitment to innovation and underscores our strategy to develop first-in-class and best-in-class therapies for serious conditions with high unmet need,” said Adam Rosenthal, Ph.D., Founder and Chief Executive Officer of Star Therapeutics. “VGA039 will be advanced by Incyte, a global biopharmaceutical leader with deep expertise in hematology and a significant commercial track record. I am immensely proud of the Star Therapeutics team and our work toward making a difference for patients with von Willebrand disease.”

VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). VGA039 has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.

The transaction has been approved by both Incyte’s and Star Therapeutics’ Boards of Directors. Under the terms of the stock purchase agreement, Incyte will acquire all the outstanding shares of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is an equity acquisition and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review resulting in an expected R&D charge of approximately $1.25 billion, that will be included in third quarter and full year 2026 GAAP and non-GAAP results.

Lazard is acting as financial advisor to Incyte and Goodwin Procter LLP is serving as its legal counsel. Evercore and Morgan Stanley are acting as financial advisors to Star Therapeutics, and Fenwick & West LLP is serving as its legal counsel.

Incyte Conference Call and Webcast
Incyte will host a conference call and webcast on Monday, June 8, 2026, at 8:00 a.m. ET to discuss the acquisition.

To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13761011. If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay, you will need the conference identification number, 13761011.

The live and archived webcast will be available via the Events and Presentations tab of the Investor section of Incyte.com.

About VGA039
VGA039 is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease (VWD). As a subcutaneously self-administered investigational antibody therapy with a convenient once monthly dosing regimen, VGA039 has the potential to meaningfully improve convenience and quality of life for patients.

VGA039 has received Fast Track, orphan drug, rare pediatric disease and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). VGA039 has advanced into a Phase 3 study (NCT07115004), VIVID-6, a global single arm cross-over study designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of VWD.

About von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). VWD patients may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1

About Star Therapeutics
Star Therapeutics is a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need. Star Therapeutics' team has invented four first-in-class antibody therapies, including the first approved drug (Enjaymo®) for cold agglutinin disease, and three other therapies that are each in Phase 3 development. For more information, please visit Star-Therapeutics.com and follow us on LinkedIn and X.

About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Incyte Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the anticipated benefits of the Vega Therapeutics acquisition; costs and other anticipated financial impacts of the acquisition; expectations regarding VGA039’s development and its potential to become an important new growth driver for Incyte’s hematology portfolio; the potential and promise VGA039 offers patients with bleeding disorders and its ability to address significant unmet need; Incyte’s strategy of building a top-tier growth company for the future; expectations regarding the closing of the proposed transaction, including the expected timing of the same; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including unexpected costs, charges or expenses resulting from the acquisition; the risk that Incyte may not be able to successfully integrate the business of Vega Therapeutics and realize the expected benefits of the acquisition in a timely manner or at all; the sufficiency of clinical trial data for VGA039, as well as Incyte’s other products and product candidates, to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for VGA039, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Incyte (INCY - Free Report) Wilmington, Delaware based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.

INCY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. INCY has a Growth Style Score of A, forecasting year-over-year earnings growth of 12.5% for the current fiscal year.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.13 to $7.65 per share. INCY also boasts an average earnings surprise of +18.3%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, INCY should be on investors' short list.

Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Key Takeaways Incyte plans to acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039.INCY expects a $1.25B R&D charge at closing, with the deal targeted to close in Q3 2026.VGA039 is in phase III testing and could become the first subcutaneous preventive VWD treatment. Incyte (INCY - Free Report) announced that it will acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for a potential consideration of up to $2 billion.

The proposed acquisition will add Vega Therapeutics’ lead candidate, VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio.

However, INCY was down 1.7% on the news probably due to high R&D charges associated with the acquisition.

INCY’s shares have gained 1.9% year to date against the industry’s decline of 3.2%.

Image Source: Zacks Investment Research

More on INCY’s Proposed Vega AcquisitionVega Therapeutics’ lead asset, VGA039, is a novel monoclonal antibody designed to improve hemostasis by modulating protein S, thereby enhancing the body's ability to control bleeding.

The therapy is being evaluated for patients with von Willebrand disease (VWD).  If approved, VGA039 could become the first subcutaneous preventive treatment for VWD, offering a more convenient dosing option compared with the frequent intravenous infusions required by existing therapies.

VWD is the most common inherited bleeding disorder, affecting approximately 135,000 people in the United States.

VGA039 has received Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, highlighting its potential to address a significant unmet need in VWD.

The candidate is currently being evaluated in the phase III VIVID-6 study (NCT07115004), a global single-arm crossover study assessing the safety and efficacy of subcutaneous VGA039 as a preventive treatment for bleeding across all VWD subtypes, including patients with severe disease burden.

Under the terms of the agreement, Star Therapeutics will receive $1.25 billion upfront and will be eligible for up to $750 million in additional milestone payments tied to future sales performance.

The acquisition has been unanimously approved by the boards of both Incyte and Star Therapeutics. Under the agreement, Incyte will acquire all outstanding shares of Vega Therapeutics, Star's wholly owned subsidiary. The transaction is expected to be closed in the third quarter of 2026, subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Upon closing, Incyte expects to record an approximately $1.25 billion in R&D charge, which will be reflected in its third-quarter and full-year 2026 results.

INCY Looks to Strengthen Pipeline/PortfolioIncyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.

At present, the lead drug Jakafi accounts for the majority of revenues.

The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.

Sales in all indications continue to be strong and should maintain momentum going forward.

Encouraging uptake of new drugs like Pemazyre and Monjuvi also contributes to its top-line growth.

Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.

Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.

Novartis also has exclusive worldwide development and commercialization rights to Tabrecta.

The Vega acquisition aligns closely with Incyte's established hematology business, allowing the company to leverage its existing R&D and commercial infrastructure while expanding its growth opportunities across both U.S. and international markets.

VGA039 is a promising late-stage hematology asset with significant commercial potential. The candidate represents a potential blockbuster opportunity with projected annual sales exceeding $1 billion and is expected to become a meaningful contributor to Incyte’s growth beyond 2029.

INCY’s Zacks Rank & Stocks to ConsiderINCY currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 85.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Immunocore’s 2026 earnings have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Incyte (INCY - Free Report) Wilmington, Delaware based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.

INCY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.8; value investors should take notice.

For fiscal 2026, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.08 to $7.64 per share. INCY boasts an average earnings surprise of +18.3%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, INCY should be on investors' short list.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Medical Properties Trust, Inc. (“Medical Properties” or the “Company”) (NYSE: MPT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON MEDICAL PROPERTIES TRUST, INC. (MPT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On March 10, 2026, Medical Properties issued a statement regarding its third-largest tenant, Healthcare Systems of America (“HAS”) stating that the Company had “sent certain ordinary course legal notices to HSA intended to protect [its] legal interests.”

HSA accounts for around 8% of the Company’s total assets. HSA is also currently engaged in competing lawsuits between two rivaling managers accusing each other of financial mismanagement and other misdeeds. This statement came shortly after Medical Properties declared a default on several of the eight properties it rents to HSA.

On this news, Medical Properties’ stock price fell $0.42, or 8.02%, to close at $4.84 per share on March 11, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Medical Properties securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From The Law Offices of Frank R. Cruz

Medical Properties Trust (MPW) remains a 'strong buy' as operational recovery accelerates and tenant issues are largely resolved. MPW's re-tenanting efforts and new leases are driving rent growth, with annualized cash rent targeted at $1 billion by year-end. Despite high net leverage (9x), MPW trades at an attractive 11.9x EV/EBITDA, well below peers, implying significant upside potential.

Medical Properties Trust (MPW) is trading at 68% of book value, with a 7% dividend yield fully covered by NFFO. MPW's $1.12 billion in contractual base rent is already on the books, with 85.9% locked in past 2035, supporting income durability. Recent real estate sales and financings validate MPW's asset base, countering the narrative that it overpaid for hospital properties.

Service Properties Trust (NASDAQ: SVC - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Investors acquired 5,000 put options on the company. This represents an increase of 523% compared to the typical volume of 803 put options. Service Properties Trust Stock Down 4.3% Shares of NASDAQ SVC opened at $2.00

-

NEWTON, Mass.--(BUSINESS WIRE)--Service Properties Trust (Nasdaq: SVC) today announced that it has commenced a $500.0 million underwritten public offering of its common shares of beneficial interest. SVC expects to use the net proceeds of this proposed offering to redeem all or a portion of the $100.0 million principal amount outstanding of its 4.95% senior notes due 2027 and/or the $450.0 million principal amount outstanding of its 5.50% senior notes due 2027. It is contemplated that the underwriters will also be granted a 30-day option to purchase up to an additional 15% of the number of common shares to be issued and sold in the proposed offering at the public offering price, less underwriting discounts and commissions.

Helix Partners (Helix) and The RMR Group (Nasdaq: RMR), SVC’s manager, have provided indications of interest to purchase up to $100.0 million and $50.0 million, respectively, of common shares in the proposed offering at the public offering price. In addition, SVC’s President and Chief Executive Officer and its Chief Financial Officer and Treasurer, as well as certain members of SVC’s Board of Trustees, have provided indications of interest to purchase common shares in the offering at the public offering price. Because these indications of interest are not binding agreements or commitments to purchase, any of these investors may determine to purchase more, fewer or no common shares in the proposed offering, or the underwriters may determine to sell more, fewer or none of our common shares to any of these investors.

In connection with the proposed offering, SVC will expand the size of the Board of Trustees to add an Independent Trustee with hotel experience in the near term, which is intended to enhance governance as SVC seeks to improve the performance of its hotel portfolio. Moreover, the entire SVC Board of Trustees is committed to maximizing shareholder value through thoughtful capital allocation between and amongst SVC’s hotel and net lease retail real estate portfolios, as SVC continues to transition its portfolio to be more focused on net lease retail real estate in the future.

Yorkville Securities is acting as lead bookrunner and Jones is acting as bookrunning manager of the proposed offering.

The offering is being made pursuant to SVC’s effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), including the base prospectus therein. A preliminary prospectus supplement relating to the offering is being filed with the SEC. When available, a copy of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Yorkville Securities, LLC at [email protected] or JonesTrading Institutional Services LLC at [email protected] or by visiting the EDGAR database on the SEC's web site at www.sec.gov.

This press release is neither an offer to sell nor a solicitation of an offer to buy common shares, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Service Properties Trust

Service Properties Trust (Nasdaq: SVC) is a real estate investment trust with approximately $10 billion invested in two asset categories: service-focused retail net lease properties and hotels. As of December 31, 2025, SVC owned 760 service-focused retail net lease properties with over 13.6 million square feet throughout the United States. As of December 31, 2025, SVC also owned 94 hotels with over 21,000 guest rooms throughout the United States and in Puerto Rico and Canada. SVC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $37 billion in assets under management as of December 31, 2025, and 40 years of institutional experience in buying, selling, financing and operating commercial real estate. SVC is headquartered in Newton, MA.

WARNING REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon SVC’s present intent, beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond SVC’s control. For example:

Although this press release refers to an offering of $500.0 million of its common shares, greater or less than $500.0 million of common shares may be sold or this proposed offering may be withdrawn and the number of common shares ultimately issued will be dependent on various factors, including the public offering price. If SVC agrees to sell common shares in the proposed offering, the closing of the proposed offering will be subject to various conditions and contingencies as are customary in underwriting agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, the sale of the common shares may not close. This press release states that SVC expects to use the net proceeds from the proposed offering to redeem all or a portion of its 4.95% senior notes due 2027 and/or 5.50% senior notes due 2027. However, the receipt and use of the proceeds is dependent on the completion of the proposed offering and may not occur and the amount of net proceeds may not be sufficient to redeem all notes. Although SVC expects to expand the size of the Board of Trustees to add an Independent Trustee with hotel experience in the near term, it may not be successful in finding or electing a suitable candidate and the nomination of any new Trustee is subject to the approval of the Trust’s Nominating and Governance Committee and the Board of Trustees, and even if a new Trustee is elected, SVC may not improve the performance of its hotel portfolio, maximize shareholder value through thoughtful capital allocation between and amongst SVC’s hotel and net lease retail real estate portfolios or further transition its portfolio to be more focused on net lease retail real estate in the future. This press release states that SVC contemplates that the underwriters will be granted an option to purchase up to an additional 15% of the number of common shares to be issued in the proposed offering. An implication of this statement may be that this option may be exercised in whole or in part. In fact, SVC does not know whether the underwriters would exercise this option, or any part of it. The information contained in SVC’s filings with the SEC, including under the caption “Risk Factors” in SVC’s periodic reports, or incorporated therein, identifies other important factors that could cause differences from SVC’s forward-looking statements. SVC’s filings with the SEC are available on the SEC’s website at www.sec.gov.

You should not place undue reliance upon forward-looking statements.

Except as required by law, SVC does not intend to update or change any forward-looking statements as a result of new information, future events or otherwise.

A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq.
No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

More News From Service Properties Trust

Back to Newsroom

SVC faces severe refinancing risk as it navigates upcoming debt maturities. SVC's $500 million equity issuance at all-time low share prices signals an inability to refinance debt through traditional channels. Leverage ratios have deteriorated, with interest coverage at 1.5x and net debt to EBITDAre near 10x, raising bankruptcy risk.

Posted by Defense World Staff on Apr 7th, 2026

Service Properties Trust (NASDAQ:SVC – Get Free Report) saw some unusual options trading activity on Monday. Stock traders acquired 8,089 call options on the stock. This represents an increase of approximately 366% compared to the average daily volume of 1,734 call options.

Insider Buying and Selling In other Service Properties Trust news, Director Adam D. Portnoy acquired 41,666,666 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were acquired at an average price of $1.20 per share, with a total value of $49,999,999.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donna D. Fraiche acquired 83,333 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $99,999.60. Following the transaction, the director owned 182,013 shares of the company’s stock, valued at $218,415.60. This represents a 84.45% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 41,914,999 shares of company stock valued at $50,297,999. 1.43% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Service Properties Trust Hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH lifted its stake in Service Properties Trust by 16.5% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,965,472 shares of the real estate investment trust’s stock valued at $8,036,000 after purchasing an additional 420,785 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Service Properties Trust in the 3rd quarter valued at about $63,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in Service Properties Trust by 8.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 179,103 shares of the real estate investment trust’s stock valued at $485,000 after purchasing an additional 14,133 shares during the last quarter. Inspire Investing LLC acquired a new stake in Service Properties Trust in the 3rd quarter valued at about $461,000. Finally, State of Alaska Department of Revenue raised its position in shares of Service Properties Trust by 34.8% in the fourth quarter. State of Alaska Department of Revenue now owns 100,281 shares of the real estate investment trust’s stock valued at $183,000 after purchasing an additional 25,884 shares during the period. 77.62% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Service Properties Trust Here are the key news stories impacting Service Properties Trust this week:

Positive Sentiment: Large director insider buys — Director Donna D. Fraiche purchased 83,333 shares (avg $1.20) and Director Rajan Penkar bought 10,000 shares in early April; both filings signal management conviction and were sizeable relative to recent trading. Donna Fraiche SEC Filing Rajan Penkar SEC Filing Positive Sentiment: CFO and multiple insiders buying — Additional insider purchases (including a CFO buy ~ $66k) and an InsiderTrades piece highlighting large insider accumulation (three insiders buying nearly 42M shares collectively) reinforce the message that insiders view current prices as attractive. CFO Purchase InsiderTrades: SVC Positive Sentiment: B. Riley upgrade — A recent upgrade by B. Riley provides sell‑side support that can attract buyers and short‑covering at these low price levels. B. Riley Upgrade Positive Sentiment: Unusually large call‑option volume — Traders bought ~8,089 SVC calls (≈366% above typical daily call volume), suggesting speculative bullish positioning that can amplify intraday upside if momentum builds. (Source: options activity report) Neutral Sentiment: Extremely heavy trading volume and volatility — The name is trading with very high volume vs. its average, which magnifies price moves in both directions and means short-term swings may be driven more by flows than fundamentals. Negative Sentiment: Pre‑market weakness — SVC dropped in pre‑market trade (reported ≈4% lower in early futures session), reflecting either profit‑taking or short‑term bearish order flow that can weigh on the open. Benzinga Pre‑Market Negative Sentiment: Weak fundamentals / capital structure risk — SVC trades at low absolute prices with a high debt‑to‑equity ratio and constrained liquidity metrics, which raises downside risk if travel/asset‑sale catalysts don’t materialize. Analyst Ratings Changes A number of brokerages have recently commented on SVC. Wall Street Zen raised shares of Service Properties Trust from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Wells Fargo & Company cut their price objective on shares of Service Properties Trust from $2.50 to $2.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Service Properties Trust in a research report on Thursday, January 22nd. Zacks Research lowered shares of Service Properties Trust from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, B. Riley Financial raised shares of Service Properties Trust from a “neutral” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Thursday, April 2nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $2.00.

Read Our Latest Report on Service Properties Trust

Service Properties Trust Stock Performance NASDAQ SVC opened at $1.31 on Tuesday. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 5.00. The firm’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $2.06. Service Properties Trust has a 1 year low of $1.13 and a 1 year high of $3.08. The firm has a market capitalization of $220.16 million, a P/E ratio of -1.08 and a beta of 1.60.

Service Properties Trust (NASDAQ:SVC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The real estate investment trust reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.16. The firm had revenue of $397.45 million for the quarter, compared to analyst estimates of $394.32 million. Service Properties Trust had a negative net margin of 11.15% and a negative return on equity of 29.70%. Service Properties Trust has set its FY 2026 guidance at 0.650-0.770 EPS.

Service Properties Trust Announces Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, February 19th. Investors of record on Monday, January 26th were paid a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 3.1%. The ex-dividend date was Monday, January 26th. Service Properties Trust’s dividend payout ratio (DPR) is -3.31%.

About Service Properties Trust (Get Free Report)

Service Properties Trust (NASDAQ: SVC) is a real estate investment trust (REIT) specializing in the acquisition, ownership and leasing of service-oriented properties, with a primary focus on the lodging sector. The company structures long-term, triple-net leases with established hotel operators under franchise agreements with leading global brands. By partnering with recognized hotel companies, Service Properties Trust seeks to generate a stable income stream through rent payments, while offering operators the capital and balance-sheet flexibility to grow their portfolios.

Since its formation in 2010, Service Properties Trust has grown its portfolio through strategic sale-leaseback transactions, targeted property acquisitions and selective dispositions.

Featured Articles Five stocks we like better than Service Properties Trust Receive News & Ratings for Service Properties Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Service Properties Trust and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAnalysts Set EZCORP, Inc. (NASDAQ:EZPW) Target Price at $28.00

NEXT HEADLINE »Head-To-Head Review: Flutter Entertainment (NYSE:FLUT) versus Churchill Downs (NASDAQ:CHDN)

-

NEWTON, Mass.--(BUSINESS WIRE)--Service Properties Trust (Nasdaq: SVC) today announced that it will issue a press release containing its first quarter 2026 results after the Nasdaq closes on Wednesday, May 6, 2026. On Thursday, May 7, 2026 at 10:00 a.m. Eastern Time, President and Chief Executive Officer Christopher Bilotto, Chief Financial Officer and Treasurer Brian Donley and Vice President Jesse Abair will host a conference call to discuss these results.

The conference call telephone number is (877) 329-3720. Participants calling from outside the United States and Canada should dial (412) 317-5434. No pass code is necessary to access the call from either number. Participants should dial in about 15 minutes prior to the scheduled start of the call. A replay of the conference call will be available through Thursday, May 14, 2026. To hear the replay, dial (855) 669-9658. The replay pass code is 1683910.

A live audio webcast of the conference call will also be available in a listen-only mode on the company’s website, which is located at www.svcreit.com. Participants wanting to access the webcast should visit the company’s website about five minutes before the call. The archived webcast will be available for replay on the company’s website after the call.

About Service Properties Trust

SVC is a real estate investment trust with approximately $10 billion invested in two asset categories: service-focused retail net lease properties and hotels. As of December 31, 2025, SVC owned 760 service-focused retail net lease properties with over 13.6 million square feet throughout the United States. As of December 31, 2025, SVC also owned 94 hotels with over 21,000 guest rooms throughout the United States and in Puerto Rico and Canada. SVC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $37 billion in assets under management as of December 31, 2025, and 40 years of institutional experience in buying, selling, financing and operating commercial real estate. SVC is headquartered in Newton, MA. For more information, visit www.svcreit.com.

A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq.
No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

More News From Service Properties Trust

Back to Newsroom

April 23, 2026  

Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in <0.5% of lead extraction procedures [1] but require immediate intervention Bridge Plus allows for rapid response when every second counts by deploying in under two minutes [2] and stopping up to 90% blood loss [3], helping stabilize patients with 30 minutes of hemostasis [4]Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S. procedures [5,*], with evidence showing improved survival when staged in advance [6,**] Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of the next-generation Bridge Plus Occlusion Balloon, designed to help electrophysiology teams rapidly control bleeding and stabilize patients during rare but life-threatening superior vena cava (SVC) tears in transvenous lead extraction (TLE) procedures. Building on technology used in more than 50,000 procedures [5*], Bridge Plus enables electrophysiology teams to respond in minutes – helping stabilize patients and buy critical time for surgical repair [2-4].

Lead extraction procedures are commonly performed to remove leads from cardiac implantable electronic devices (CIEDs), such as pacemakers or defibrillators, due to damaged, infected or malfunctioning leads. While there is evidence of lead extraction’s safe use [7,8], SVC tears, occurring in fewer than 0.5% of cases [1], can quickly become fatal without immediate intervention.

Bridge Plus is designed to provide temporary vessel occlusion, helping reduce blood loss, maintain hemostasis, and stabilize patients during emergencies. The balloon can deploy in less than two minutes [2], stop up to 90% blood loss [3], and maintain acceptable hemostasis for at least 30 minutes [4]. This provides physicians with critical time to stabilize patients and prepare for surgical repair.

“Ensuring procedural safety is a top priority for electrophysiology teams,” said Stacy Beske, Business Leader, Image-Guided Therapy Devices at Philips. “Bridge Plus builds on established technology to help physicians prepare for rare SVC tears and respond quickly with the control needed to stabilize patients and transition to surgery.”

Clinical evidence highlights the importance of being prepared for this emergency scenario, with studies showing that survival rates in SVC tear events improved from 56.9% to 88.2% when an occlusion balloon was staged and available during procedures [6, 7].

“Although superior vena cava tears are rare, they represent one of the most critical emergencies that can occur during lead extraction,” said Dr. Thomas Callahan, an electrophysiologist at Cleveland Clinic who studied the technology***. “Having an occlusion balloon staged and ready can significantly improve response time when every second matters. This technology may help teams prepare for these rare but serious events and support safer lead extraction procedures.”

Prophylactic balloon set up brings additional benefits during TLE procedures, including individualized balloon staging for each patient, and the ability to deploy Bridge Plus if fluoroscopy is no longer available.

Bridge Plus is a low-pressure, compliant occlusion balloon with radiopaque markers designed for accurate placement and compatibility with a wide range of patient anatomies [9]. The device expands Philips’ portfolio of lead management solutions supporting safe and effective extraction procedures.

The Bridge Plus Occlusion Balloon is now commercially available in the United States, with international availability expected later in 2026, pending country registrations. The solution will also be showcased at Heart Rhythm Society (HRS) 2026, taking place April 24-26 in Chicago, IL.

For more information, visit the Philips Bridge Plus Occlusion Balloon product page.

*Cases performed in United States since Bridge launch in 2016. 
** When staging the Bridge Balloon versus when no Bridge balloon is used.
*** Dr. Callahan discloses consulting payments from Philips North America LLC for training and education services.

[1] Azarrafiy, Ryan et al. “Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multiyear Analysis and an Update to Best Practice Protocol.” Circulation. Arrhythmia and electrophysiology vol. 12,8 (2019): e007266. doi:10.1161/CIRCEP.119.007266.
[2] Document on file D002023609_A_Bridge M&M Marketing Claims Test Report. Average timed deployment for commercial Bridge was 74.33 seconds (n=6) and Bridge Plus was 58.33 seconds (n=6).
[3] Document on File, D027561 Marketing claims blood loss report for Bridge project 1338 - When deployed, the Bridge Occlusion Balloon reduces blood loss of an SVC tear by 89.7% (α=0.10), on average, in an animal model.
[4] Document on file, D026197 & animal study - NGX028-IS17 - All animals had biological metrics measured for up to 45 minutes during occlusion and 15 minutes post device deployment.
[5] Document on file. LT-002760 Bridge Sales Customers Raw Data.
[6] Bruce L. Wilkoff, MD, FHRS, Roger G. Carrillo, MD, MBA, FHRS, Ryan Azarrafiy, BA, Darren C. Tsang, BS, Thomas A. Boyle, BS. Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions.
[7] Wazni 0, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExlCon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll cardiol. 2010;55(6):579-586.
[8] Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38(40):2995-3005.
[9] Document on file, D026203 Engineering Translation Rationale For Bridge, Project #1338 – PR00. The balloon will cover the length and diameter of the SVC in 90% of the population as determined by analysis of 52 patients.

For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 610 558 116
E-mail: [email protected]

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Clinical illustration of the Philips Bridge Plus balloon in use The Philips Bridge Plus Balloon, uninflated prior to use The inflated Philips Bridge Plus Balloon

Service Properties (SVC - Free Report) came out with quarterly funds from operations (FFO) of $0.04 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to FFO of $0.07 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of -57.90%. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.01 per share when it actually produced FFO of $0.17, delivering a surprise of +1600%.

Over the last four quarters, the company has surpassed consensus FFO estimates two times.

Service Properties, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $364.45 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 6.28%. This compares to year-ago revenues of $435.18 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

Service Properties shares have lost about 16.3% since the beginning of the year versus the S&P 500's gain of 6%.

What's Next for Service Properties?While Service Properties has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Service Properties was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.18 on $390.16 million in revenues for the coming quarter and $0.49 on $1.49 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Gladstone Land (LAND - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This real estate investment trust specializing in farmland is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of -83.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Gladstone Land's revenues are expected to be $14.2 million, down 15.5% from the year-ago quarter.

2 hours ago

MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in StockMarketBeat

MSA Safety Incorporporated (NYSE:MSA - Get Free Report) CFO Julie Beck bought 448 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $158.69 per share, with a total value of $71,093.12. Following the completion of the purchase, the chief financial officer owned 3,825 shares of the company's stock, valued at $606,989.25. This represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NYSE:MSA

Read MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in Stock

2 hours ago

Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of StockMarketBeat

NBT Bancorp Inc. (NASDAQ:NBTB - Get Free Report) Director Heidi Hoeller sold 2,100 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $48.03, for a total transaction of $100,863.00. Following the transaction, the director owned 11,560 shares of the company's stock, valued at approximately $555,226.80. This represents a 15.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:NBTB

Read Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of Stock

2 hours ago

Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) StockMarketBeat

IGM Financial Inc. (TSE:IGM - Get Free Report) Director Douglas Milne sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of C$80.61, for a total value of C$128,976.00. Following the sale, the director directly owned 800 shares in the company, valued at C$64,488. The trade was a 66.67% decrease in their ownership of the stock.

TSE:IGM

Read Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) Stock

2 hours ago

GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 SharesMarketBeat

GlobalFoundries Inc. (NASDAQ:GFS - Get Free Report) insider Michael James Hogan sold 2,800 shares of GlobalFoundries stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $75.17, for a total value of $210,476.00. Following the transaction, the insider owned 6,695 shares in the company, valued at $503,263.15. This trade represents a 29.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NASDAQ:GFS

Read GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 Shares

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 325

-

NEWTON, Mass.--(BUSINESS WIRE)--Service Properties Trust (Nasdaq: SVC) today announced that President and Chief Executive Officer Chris Bilotto and Chief Financial Officer and Treasurer Brian Donley will be presenting at Nareit’s REITweek 2026 Investor Conference in New York, NY on Wednesday, June 3, 2026 at 9:30 a.m. Eastern Time.

A live audio webcast of the presentation will be available in a listen-only mode on the company’s website at https://www.svcreit.com/investors/Events-and-presentations. Participants wanting to access the webcast should visit the company’s website about 15 minutes before the start of the presentation.

About Service Properties Trust

SVC is a real estate investment trust with $9.9 billion invested in two asset categories: service-focused retail net lease properties and hotels. As of March 31, 2026, SVC owned 761 service-focused retail net lease properties with over 13.6 million square feet throughout the United States and 93 hotels with over 21,000 guest rooms throughout the United States, including Puerto Rico, and Canada. SVC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $37 billion in assets under management as of March 31, 2026, and 40 years of institutional experience in buying, selling, financing and operating commercial real estate. SVC is headquartered in Newton, MA. For more information, visit www.svcreit.com.

More News From Service Properties Trust

Back to Newsroom

Key Takeaways Terreno Realty sold a 99,000 sq. ft. Torrance industrial property for $31.1M on April 7, 2026.TRNO acquired the property in 2018 for $17.5M, generating a 10.3% unleveraged IRR.Terreno Realty's 2025 dispositions totaled $386.4M, including $144.2M in Q4 sales. Terreno Realty Corporation (TRNO - Free Report) announced the disposition of an industrial property located in Torrance, CA. The sale was carried out on April 7, 2026, for approximately $31.1 million.

The property spans across 99,000 square feet on 4.7 acres, which is 100% leased. Terreno Realty had purchased the property on Jan. 31, 2018, for $17.5 million. The investment yielded an unleveraged internal rate of return of 10.3% to the company.

Terreno Realty’s dispositions are an integral part of its ongoing efforts to optimize its portfolio and enhance its financial performance. In the fourth quarter of 2025, the company sold properties worth $144.2 million. Total dispositions for the year 2025 aggregated $386.4 million.

Wrapping Up on TRNOWhile the sale could lead to a slight near-term decline in rental income if the asset was contributing to revenues, reinvestment of the proceeds into higher-yielding opportunities is expected to support long-term earnings growth. The transaction may also enhance the company’s liquidity and financial flexibility, enabling it to fund future investments or manage its balance sheet more efficiently.

Over the past three months, shares of this Zacks Rank #2 (Buy) company have increased 7.8% compared with the industry's growth of 4.4%. Analysts seem bullish on this industrial REIT, with its 2026 FFO per share estimate moving 3 cents northward to $2.79 over the past two months.

Image Source: Zacks Investment Research

Other Stocks to ConsiderSome other top-ranked stocks from the broader REIT sector are Prologis (PLD - Free Report) and Ventas (VTR - Free Report) , each carrying a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for PLD’s 2026 FFO per share is pegged at $6.14, which indicates year-over-year growth of 5.7%.

The Zacks Consensus Estimate for VTR’s full-year FFO per share stands at $3.84, which calls for an increase of 10.3% from the year-ago period.

Note: Anything related to earnings presented in this write-up represents FFO, a widely used metric to gauge the performance of REITs.

BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has completed the development and stabilization of Countyline Corporate Park Phase IV Building 34 in Hialeah, Florida. Building 34 is 100% leased to three tenants. Building 34 of Terreno Realty Corporation’s Countyline Corporate Park is a 220,000 square foot 36-foot clear height rear-load industrial distribution building on 13.0 acres with 76 dock-high and two grade-level loading positions and parking for 188 cars. The building is expected to achieve LEED certification, the total investment is $55.3 million and the estimated stabilized cap rate is 5.7%.

Countyline Corporate Park Phase IV consists of a 121-acre project entitled for 2.2 million square feet of industrial distribution buildings in Miami’s Countyline Corporate Park (“Countyline”), immediately adjacent to Terreno Realty Corporation’s seven buildings within Countyline (Countyline Corporate Park Phase III). Countyline is a landfill redevelopment adjacent to Florida’s Turnpike and the southern terminus of I-75 located at the intersection of NW 170th Street and NW 107th Avenue. At expected completion in 2027, Countyline Phase IV is expected to contain ten LEED-certified industrial distribution buildings totaling approximately 2.2 million square feet providing 660 dock-high and 22 grade-level loading positions and parking for 1,875 cars for a total expected investment of approximately $508.5 million.

Taken together, Terreno Realty Corporation’s Countyline Corporate Park Phase III and IV will contain 17 industrial distribution buildings and 3.5 million square feet.

Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy (generally 95%) divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer’s due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey; Los Angeles; Miami; San Francisco Bay Area; Seattle and Washington, D.C.

Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management’s beliefs and on assumptions made by, and information currently available to, management. When used, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “result,” “should,” “will,” “seek,” “target,” “see,” “likely,” “position,” “opportunity,” “outlook,” “potential,” “enthusiastic,” “future” and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.

BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has executed an early lease renewal for 68,000 square feet in Washington, D.C. with a provider of educational services. The lease will commence December 1, 2026 and expire December 2031.

Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey; Los Angeles; Miami; San Francisco Bay Area; Seattle; and Washington, D.C.

Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management’s beliefs and on assumptions made by, and information currently available to, management. When used, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “result,” “should,” “will,” “seek,” “target,” “see,” “likely,” “position,” “opportunity,” “outlook,” “potential,” “enthusiastic,” “future” and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.

Posted by Defense World Staff on Apr 23rd, 2026

Boston Trust Walden Corp lowered its stake in shares of Terreno Realty Corporation (NYSE:TRNO – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 447,965 shares of the real estate investment trust’s stock after selling 27,054 shares during the period. Boston Trust Walden Corp owned about 0.43% of Terreno Realty worth $26,300,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Terreno Realty by 95.8% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 106,766 shares of the real estate investment trust’s stock worth $6,268,000 after purchasing an additional 52,230 shares in the last quarter. Evergreen Capital Management LLC increased its stake in shares of Terreno Realty by 6.9% during the fourth quarter. Evergreen Capital Management LLC now owns 6,595 shares of the real estate investment trust’s stock worth $390,000 after purchasing an additional 423 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Terreno Realty by 4.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 72,209 shares of the real estate investment trust’s stock worth $4,239,000 after purchasing an additional 2,937 shares in the last quarter. First Horizon Corp increased its stake in shares of Terreno Realty by 41.5% during the fourth quarter. First Horizon Corp now owns 651 shares of the real estate investment trust’s stock worth $38,000 after purchasing an additional 191 shares in the last quarter. Finally, Moran Wealth Management LLC increased its stake in shares of Terreno Realty by 11.1% during the fourth quarter. Moran Wealth Management LLC now owns 21,317 shares of the real estate investment trust’s stock worth $1,252,000 after purchasing an additional 2,127 shares in the last quarter.

Terreno Realty Stock Down 0.4% Shares of NYSE TRNO opened at $65.98 on Thursday. Terreno Realty Corporation has a 12-month low of $53.00 and a 12-month high of $67.55. The stock has a market cap of $7.01 billion, a PE ratio of 16.92 and a beta of 1.12. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average of $63.99 and a 200 day moving average of $61.93.

Terreno Realty (NYSE:TRNO – Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The real estate investment trust reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.68. The company had revenue of $137.48 million during the quarter, compared to analysts’ expectations of $124.72 million. Terreno Realty had a net margin of 84.51% and a return on equity of 10.08%. As a group, sell-side analysts predict that Terreno Realty Corporation will post 2.79 EPS for the current fiscal year.

Terreno Realty Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, April 10th. Shareholders of record on Friday, March 27th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 3.2%. The ex-dividend date was Friday, March 27th. Terreno Realty’s payout ratio is presently 53.33%.

Wall Street Analyst Weigh In A number of research firms have recently commented on TRNO. Weiss Ratings raised shares of Terreno Realty from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, January 22nd. Barclays reaffirmed a “positive” rating and set a $60.00 price objective on shares of Terreno Realty in a research note on Tuesday, January 13th. Citigroup upped their price objective on shares of Terreno Realty from $64.00 to $70.00 and gave the company a “neutral” rating in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $72.00 price objective on shares of Terreno Realty in a research note on Monday, February 9th. Finally, Piper Sandler upped their price objective on shares of Terreno Realty from $75.00 to $79.00 and gave the company an “overweight” rating in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.36.

Read Our Latest Analysis on Terreno Realty

Terreno Realty Profile (Free Report)

Terreno Realty Corporation (NYSE: TRNO) is a real estate investment trust specializing in the acquisition, ownership and operation of industrial properties in key coastal markets across the United States. The company’s portfolio primarily consists of bulk distribution, warehouse and light-industrial assets that serve a diverse tenant base, including third-party logistics providers, e-commerce companies and manufacturers. Terreno aims to generate stable rental income while pursuing long-term capital appreciation through targeted investment and active asset management.

Terreno focuses on eight major coastal regions, emphasizing markets with strong supply-and-demand fundamentals and barriers to new development.

Featured Stories Five stocks we like better than Terreno Realty Want to see what other hedge funds are holding TRNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terreno Realty Corporation (NYSE:TRNO – Free Report).

Receive News & Ratings for Terreno Realty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terreno Realty and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECwm LLC Acquires 3,690 Shares of Emerson Electric Co. $EMR

NEXT HEADLINE »Cwm LLC Grows Stock Position in First Trust TCW Opportunistic Fixed Income ETF $FIXD

Terreno Realty Corporation (TRNO) is rated a Buy with a $70 price target, supported by strong Q1 2026 earnings and a robust development pipeline. TRNO's infill, supply-constrained coastal market focus underpins high occupancy (96.3%) and resilient same-store NOI growth, reinforcing its structural competitive advantage. The REIT maintains a conservative balance sheet (net debt/EBITDA 2.5x) and consistent dividend growth (11.6% CAGR since 2011), with a well-covered 3.17% forward yield.

Terreno Realty Corporation NYSE:TRNO , an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, acquired an industrial property located in San Francisco, California on June 4, 2026 for a purchase price of approximately $25.9 million.

The property consists of one industrial distribution building containing approximately 65,000 square on 3.8 acres. The property is at 201-395 Mendell Street, in San Francisco’s India Basin neighborhood, and provides 17 dock-high and 10 grade-level loading positions and parking for 95 cars. The building is 100% leased to four tenants all of which expire by May 2031. The estimated stabilized cap rate is 5.5%.

Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy (generally 95%) divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer’s due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey, Los Angeles, Miami, San Francisco Bay Area, Seattle and Washington, D.C.

Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. We caution investors that forward-looking statements are based on management’s beliefs and on assumptions made by, and information currently available to, management. When used, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “result,” “should,” “will,” “seek,” “target,” “see,” “likely,” “position,” “opportunity,” “outlook,” “potential,” “enthusiastic,” “future” and similar expressions which do not relate solely to historical matters are intended to identify forward-looking statements. These statements are subject to risks, uncertainties, and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control, including risks related to our ability to meet our estimated forecasts related to stabilized cap rates, and those risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other public filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, or projected. We expressly disclaim any responsibility to update our forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528334649/en/

Key Takeaways Terreno Realty acquired a 65,000-square-foot industrial property in San Francisco for $25.9 million.TRNO's newly acquired asset is fully leased to four tenants through May 2031 with a 5.5% cap rate.TRNO reported portfolio leasing of 96.3% for buildings and 96.6% for improved land parcels. Terreno Realty Corporation (TRNO - Free Report) recently announced the acquisition of an industrial property in San Francisco, CA. The buyout was completed on June 4 for a purchase price of approximately $25.9 million.

Located at 201-395 Mendell Street in San Francisco’s India Basin neighborhood, the property comprises roughly 65,000 square feet across 3.8 acres. The facility features 17 dock-high and 10 grade-level loading positions and parking capacity for 95 vehicles. The property is fully leased to four tenants through May 2031 and is expected to generate a stabilized cap rate of approximately 5.5%.

The acquisition aligns with Terreno Realty’s ongoing portfolio optimization strategy. During the first quarter of 2026, the company acquired two industrial properties for a combined investment of approximately $103.2 million. Over the same period, it sold two properties for total proceeds of $55.1 million, reflecting a disciplined approach to capital allocation and balance sheet management.

Through strategic acquisitions and dispositions, Terreno Realty continues to strengthen its presence across six major coastal U.S. markets: New York City/Northern New Jersey, Los Angeles, Miami, the San Francisco Bay Area, Seattle and Washington, D.C. These regions benefit from favorable demographic trends, strong consumption patterns and sustained demand for industrial real estate.

TRNO’s portfolio continues to exhibit strong occupancy, with buildings 96.3% leased and improved land parcels 96.6% leased as of March 31, 2026. The company’s focus on high-quality infill industrial assets in supply-constrained coastal logistics markets should support favorable leasing dynamics, continued rent growth and long-term value creation, although results remain subject to local market conditions and tenant demand.

TRNO’s key risks include its concentration in a limited number of coastal markets and near-term lease rollover exposure. Any slowdown in tenant demand or weaker market rents could pressure occupancy and leasing spreads.

Shares of this Zacks Rank #3 (Hold) company have gained 5.1% over the past six months compared with the industry’s growth of 10.3%.

Image Source: Zacks Investment Research

Stocks to ConsiderSome better-ranked stocks from the broader REIT sector are Cousins Properties (CUZ - Free Report) and Lamar Advertising (LAMR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for CUZ’s 2026 FFO per share has been revised up marginally over the past two months to $2.93.

The consensus estimate for LAMR’s 2026 FFO per share has been revised northward 2.1% to $8.81 over the past month.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.